Kura Oncology (KURA) to Release Quarterly Earnings on Wednesday
Kura Oncology (NASDAQ:KURA) is scheduled to release its Q4 2025 earnings before the market opens on Wednesday, February 25, 2026, with analysts anticipating a loss of ($0.42) per share. The company's stock opened at $8.48, and recent insider selling activity has been noted, with several institutional investors also adjusting their positions. Wall Street analysts currently have a "Moderate Buy" consensus rating for KURA, with an average price target of $28.00.
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline
Kura Oncology (KURA) is expected to report a significant year-over-year decline in earnings and lower revenues for Q4 2025. The company is projected to post a quarterly loss of $0.72 per share, with revenues around $29.81 million. The Zacks Earnings ESP indicates a potential negative surprise, making it difficult to predict an earnings beat.
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline
Kura Oncology (KURA) is expected to report a year-over-year decline in Q4 earnings and lower revenues for the quarter ended December 2025. The consensus EPS estimate has been revised significantly lower, and the company has a negative Earnings ESP and a Zacks Rank of #4, making an earnings beat difficult to predict. Investors are advised to consider other factors beyond just earnings surprise when evaluating the stock.
Liquidity Mapping Around (KURA) Price Events
This article provides a detailed analysis of Kura Oncology Inc. (NASDAQ: KURA) stock, highlighting a positive near-term sentiment within a long-term bullish context, despite a weak mid-term bias. It outlines exceptional risk-reward opportunities with a target gain of 22.4% and presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes the potential for significant gains if support holds, urging investors to consider these strategies.
Kura Oncology (NASDAQ:KURA) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Kura Oncology (NASDAQ:KURA) from "hold" to "sell," despite other firms maintaining "buy" or "overweight" ratings and a MarketBeat consensus of "Moderate Buy" with a $28.00 average target price. The clinical-stage biopharmaceutical company's shares traded around $8.31, with a market cap of approximately $723 million, reflecting its loss-making operations. Insider transactions show recent sales, with insiders owning about 6.4% of the stock.
The Truth About Kura Oncology Inc: Is This Sleeper Cancer Stock About To Explode?
Kura Oncology Inc (KURA) is a clinical-stage oncology company developing targeted cancer therapies, generating significant buzz in biotech communities for its potential as a high-risk, high-reward investment. While not a meme stock, its volatility makes it attractive to both long-term biotech enthusiasts and short-term traders. Investors should note its scientific pipeline is the primary value driver, and its share price will be heavily influenced by clinical trial results, regulatory updates, and potential partnerships, making it a speculative add-on for high-risk tolerance portfolios rather than a core holding.
Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026
Analysts have significantly revised down Kura Oncology, Inc.'s revenue estimates for 2026, alongside an increase in loss per share forecasts. The new consensus predicts revenues of US$139m and losses of US$3.31 per share, reflecting a more conservative outlook. Despite these downgrades, the company's projected revenue growth of 26% annually is still expected to outpace the industry average.
Kura Oncology gives new hires options on 69,750 shares at $8.27
Kura Oncology announced the grant of inducement nonstatutory stock options for 69,750 shares to four new employees. These options have an exercise price of $8.27, matching the closing price on February 2, 2026, and will vest over four years. This move, approved under Nasdaq Listing Rule 5635(c)(4), aims to incentivize new hires.
Kura Oncology Grants Inducement Stock Options to New Employees as Part of 2023 Inducement Option Plan
Kura Oncology announced the grant of inducement stock options to four new employees, totaling 69,750 shares, under its 2023 Inducement Option Plan. The options have an exercise price of $8.27 per share and will vest over four years, aligning with Nasdaq regulations. This move aims to attract and retain talent in the biopharmaceutical company, which specializes in cancer treatments and has an FDA-approved drug, KOMZIFTI™.
Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026
Analysts have significantly revised down Kura Oncology, Inc.'s revenue estimates for 2026, from US$158m to US$139m, while also increasing loss per share forecasts to US$3.31. Despite these downgrades, the consensus price target remains unchanged, and the company's projected revenue growth rate for 2026 is still expected to outpace the broader industry. Investors are advised to consider the long-term prospects beyond next year's earnings.
Why (KURA) Price Action Is Critical for Tactical Trading
This article analyzes Kura Oncology Inc. (NASDAQ: KURA) stock, highlighting weak near and mid-term sentiment despite a positive long-term outlook. It provides specific AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses. The analysis emphasizes elevated downside risk and the importance of tactical trading based on multi-timeframe signals.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced inducement grants of nonstatutory stock options to four new employees, totaling 69,750 shares of common stock. These grants were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $8.27 per share and will vest over four years, contingent on continued employment.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced inducement awards granted to four new employees, consisting of nonstatutory stock options to purchase 69,750 shares of common stock. These awards were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), with an exercise price of $8.27 per share and a four-year vesting schedule. The company, a biopharmaceutical firm focused on precision medicines for cancer, highlights its KOMZIFTI™ product and ongoing advancements.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology announced inducement awards of nonstatutory stock options to four new employees, as approved by the Compensation Committee. These grants, totaling 69,750 shares, are intended to fulfill employment inducements under Nasdaq Listing Rule 5635(c)(4). The stock options, with an exercise price of $8.27 per share, will vest over four years, subject to continued employment.
Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion
An analyst flagged Kura Oncology, Inc. (KURA) for its upcoming 2026 milestones and pipeline expansion, despite Leerink Partners lowering its price target to $20 from $25 while maintaining an Outperform rating. Kura Oncology recently reported $2.1 million in net product sales for KOMZIFTI, its oral menin inhibitor, within its first five weeks of commercial availability. The company is focused on expanding KOMZIFTI into combination regimens and non-AML indications, increasing its commercial use, and progressing current AML clinical investigations.
Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion
An analyst flagged Kura Oncology, Inc. (KURA) for its anticipated 2026 milestones and pipeline expansion. Despite Leerink Partners lowering their price target to $20 from $25, they maintained an Outperform rating. Kura Oncology recently reported $2.1 million in net product sales for KOMZIFTI, its oral menin inhibitor, within five weeks of commercial launch and outlined plans for expanding ziftomenib's indications and ongoing clinical investigations.
Nan Fung Trinity HK Ltd. Invests $2.04 Million in Kura Oncology, Inc. $KURA
Nan Fung Trinity HK Ltd. has recently invested $2.04 million in Kura Oncology, acquiring a 0.27% stake. This move is part of a broader trend of increased institutional interest, with several other firms also boosting their positions. Analyst sentiment is mixed but leans towards "Moderate Buy," despite recent insider selling and an EPS miss for Kura Oncology.
Kura Oncology, Inc. (KURA) Growth Potential: Analyst Ratings Suggest A 295.93% Upside
Kura Oncology, Inc. (KURA) shows significant growth potential with 13 buy ratings and only two holds from analysts, projecting an average target price of $32.55, representing a 295.93% upside from its current $8.22. The clinical-stage biopharmaceutical company, focused on cancer therapies, has a promising pipeline including ziftomenib and tipifarnib, reinforced by strategic collaborations. Despite current financial challenges typical of early-stage biotech, its innovative focus and robust analyst support make it an appealing prospect for growth-oriented investors with a higher risk tolerance.
Don't Ignore The Insider Selling In Kura Oncology
The article highlights recent insider selling at Kura Oncology (NASDAQ: KURA), specifically a sale by the Chief Legal Officer, Teresa Bair. While there was a significant purchase by Chairman Troy Wilson previously, the overall trend for the last year shows more insider selling than buying. Despite insiders owning 1.6% of the company, the article suggests caution due to the recent selling activity and advises investors to look for significant insider buys before considering the stock.
Don't Ignore The Insider Selling In Kura Oncology
Kura Oncology's Chief Legal Officer recently sold US$95k worth of stock, reducing her holding by 9.0%. While there was a larger insider purchase by Chairman Troy Wilson in the past year at a higher price, overall insider selling has outweighed buying. Insiders collectively own 1.6% of the company, and the article suggests caution despite this ownership due to the history of sales.
Kura Oncology Tightens Governance with Amended Bylaws
Kura Oncology (KURA) updated its corporate bylaws on January 28, 2026, to enhance governance regarding shareholder meetings, director nominations, and proposals. These revisions include stricter advance notice requirements, updated voting standards, and stronger protections for directors, aiming to reinforce the company's control over corporate procedures. Despite significant operating losses, Spark, TipRanks' AI Analyst, rates KURA as Neutral, citing strong clinical execution and a cash runway through 2027.
Don't Ignore The Insider Selling In Kura Oncology
Kura Oncology's Chief Legal Officer and Corporate Secretary recently sold US$95k worth of stock. While there was a significant insider purchase by the Chairman earlier at a higher price, net insider transactions over the last year show more selling than buying. The average sell price was higher than the current stock price, and while there's insider ownership, the history of sales suggests caution.
Kura Oncology CCO Powl sells $54,266 in stock
Brian T. Powl, Chief Commercial Officer of Kura Oncology (NASDAQ:KURA), sold 6,414 shares of common stock for approximately $54,266 to cover tax obligations from vested Restricted Stock Units. The sales occurred in two transactions on January 27, 2026. This news follows Kura Oncology's recent milestone of completing its first U.S. commercial sale of KOMZIFTI, a new AML treatment, which triggered a $135 million payment and inclusion in NCCN guidelines.
Kura Oncology COO Ford sells $15,339 in stock
Kathleen Ford, COO of Kura Oncology, sold 1,813 shares of stock worth $15,339 to cover taxes related to restricted stock unit vesting. This comes as Kura Oncology recently announced the first U.S. commercial sale of its leukemia drug KOMZIFTI, triggering a $135 million milestone payment, and received a "Market Outperform" rating from Citizens. These developments highlight Kura's advancements in the oncology sector.
Kura oncology CSO Burrows sells $11k in shares
Kura Oncology's Chief Scientific Officer, Francis Burrows, sold 1,311 shares worth approximately $11,091 to cover taxes related to a restricted stock unit vesting. Despite this sale, Kura Oncology appears undervalued with strong financial flexibility and recently completed its first US commercial sale of KOMZIFTI, triggering a significant milestone payment. Analysts maintain a "Market Outperform" rating on the stock, citing the potential of its menin inhibitor ziftomenib.
Kura Oncology’s chief medical officer, Leoni, sells $69k in stock By Investing.com
Mollie Leoni, Chief Medical Officer of Kura Oncology, Inc., sold 8,182 shares of common stock for approximately $69,208 to cover tax obligations related to vested Restricted Stock Units. This transaction occurred as Kura Oncology's stock trades below its InvestingPro Fair Value, despite recent growth. The company recently completed its first U.S. commercial sale of KOMZIFTI, triggering a $135 million milestone payment, and maintains a Market Outperform rating from Citizens.
Kura Oncology CCO Powl sells $54,266 in stock By Investing.com
Brian T. Powl, Chief Commercial Officer of Kura Oncology, Inc., sold 6,414 shares of common stock for approximately $54,266 to cover tax obligations from vested Restricted Stock Units. This insider sale comes amidst significant company news, including the first U.S. commercial sale of KOMZIFTI, which triggered a $135 million payment from Kyowa Kirin, and its inclusion in National Comprehensive Cancer Network guidelines. Citizens also maintained a Market Outperform rating for Kura Oncology with a $24.00 price target.
Kura oncology CSO Burrows sells $11k in shares
Kura Oncology's Chief Scientific Officer, Francis Burrows, sold 1,311 shares worth approximately $11,091 to cover taxes from a restricted stock unit vesting. This transaction occurred as the company announced its first U.S. commercial sale of KOMZIFTI, triggering a significant milestone payment and receiving a Market Outperform rating from Citizens.
Kura Oncology’s chief legal officer sells $94,827 in stock
Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, sold 11,208 shares of company stock for approximately $94,827 to cover tax obligations from vested Restricted Stock Units. Following the transaction, Bair directly holds 226,931 shares. This news follows recent company milestones, including the first U.S. commercial sale of KOMZIFTI and a maintained "Market Outperform" rating from Citizens.
Kura Oncology SVP sells $60k in shares
Thomas James Doyle, SVP, Finance & Accounting at Kura Oncology (NASDAQ: KURA), sold 7,141 shares for $60,426 on January 27, 2026, primarily to cover tax obligations related to Restricted Stock Units. Despite a recent YTD stock decline, the company shows strong balance sheet metrics and recently completed its first commercial sale of KOMZIFTI, triggering a $135 million milestone payment. Citizens has maintained a Market Outperform rating with a $24.00 price target, highlighting Kura's progress in the oncology sector.
Kura Oncology COO Ford sells $15,339 in stock
Kathleen Ford, COO of Kura Oncology (NASDAQ:KURA), sold 1,813 shares of common stock worth $15,339 to cover taxes related to a restricted stock unit vesting. This transaction occurred on January 27, 2026, and leaves her with 153,560 directly owned shares. The company recently announced a $135 million milestone payment for its leukemia drug KOMZIFTI following its first U.S. commercial sale and FDA approval, and analysts maintain a positive outlook on the stock.
Understanding Momentum Shifts in (KURA)
This article analyzes Kura Oncology Inc. (NASDAQ: KURA), highlighting divergent sentiment across different time horizons and indicating choppy market conditions. It identifies an exceptional 94.0:1 risk-reward setup, targeting a 23.1% gain versus 0.2% risk. The analysis also provides specific institutional trading strategies for long, breakout, and short positions, along with multi-timeframe signal analysis.
Sector Gamma AS Takes $3.88 Million Position in Kura Oncology, Inc. $KURA
Sector Gamma AS has acquired a new stake of 438,415 shares in Kura Oncology, Inc. valued at approximately $3.88 million. This move comes as insiders have been net sellers, disposing of over $730,000 worth of shares in the last three months. Analyst sentiment remains largely positive, with an average "Moderate Buy" rating and a price target of $28.00.
Kura Oncology (NASDAQ:KURA) Cut to "Strong Sell" at Zacks Research
Zacks Research downgraded Kura Oncology (NASDAQ:KURA) from a "hold" to a "strong sell" rating. Despite this downgrade, the broader analyst consensus remains "Moderate Buy" with an average target price of $28.00. The company recently missed EPS estimates and has experienced insider selling, alongside negative financial metrics.
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Up 37.5% in December
Kura Oncology, Inc. (NASDAQ:KURA) experienced a significant 37.5% increase in short interest during December, reaching 11.31 million shares, which represents 13.9% of its stock. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $28.00, despite recent insider selling totaling 68,343 shares. Kura Oncology is a clinical-stage biopharmaceutical company focusing on targeted oncology therapies, with its lead candidate tipifarnib, a farnesyltransferase inhibitor.
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Kura Oncology announced its recent accomplishments, preliminary KOMZIFTI™ revenue, and anticipated 2026 milestones. The company reported $2.1 million in KOMZIFTI net product revenue for late 2025 following its FDA approval in November 2025 for R/R NPM1-mutated AML. Kura Oncology also outlined a comprehensive development strategy for KOMZIFTI, aiming to expand its use and advance its pipeline programs, while reporting a strong cash position of $667.3 million.
Kura Oncology's finance SVP sells shares worth $38,958
Kura Oncology's Senior Vice President of Finance, Stephen Dalton, sold 3,000 shares of the company's stock at an average price of $12.98 per share, totaling $38,940. This transaction was disclosed in a Form 4 filing with the SEC. Dalton now directly owns 46,712 shares of Kura Oncology.
Kura Oncology price target lowered to $20 from $25 at Leerink
Leerink has lowered its price target for Kura Oncology (KURA) to $20 from $25, while maintaining an Outperform rating on the shares. This adjustment comes ahead of the company's Q4 earnings report and reflects model updates based on preliminary Q4 financial results, including Komzifti net product revenue and collaboration revenue, as well as 2026 financial guidance.
FY2025 EPS Forecast for Kura Oncology Reduced by Analyst
Brookline Capital Management has reduced its FY2025 EPS estimate for Kura Oncology (NASDAQ:KURA) to ($2.90) from ($2.87), which is below the consensus estimate. The company recently reported Q3 EPS of ($0.85), missing analyst expectations, despite revenue of $20.75 million exceeding estimates. Despite the lowered forecast and past earnings miss, analysts maintain a "Moderate Buy" consensus rating with an average price target significantly above the current share price.
Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), Health Catalyst (HCAT)
Two healthcare stocks, Kura Oncology (KURA) and Health Catalyst (HCAT), have received bullish sentiments from analysts. Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kura Oncology with a $40.00 price target, while Ryan Daniels from William Blair maintained a Buy rating on Health Catalyst. Both companies have a consensus rating of either Strong Buy or Moderate Buy, indicating positive outlooks from the analyst community.
Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright
HC Wainwright reaffirmed a "Buy" rating for Kura Oncology (NASDAQ:KURA) with a $40.00 price target, implying a significant upside. Despite missing EPS estimates, Kura Oncology surpassed revenue expectations, and institutional investors have increased their stakes, even as insiders sold shares. Other analysts also maintain positive ratings on the stock, contributing to a consensus "Moderate Buy" rating.
Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA)
Two healthcare companies, Cerus (CERS) and Kura Oncology (KURA), have received bullish sentiments from analysts. TD Cowen analyst Josh Jennings reiterated a Buy rating for Cerus with a $5.00 price target, while TD Cowen analyst Phil Nadeau maintained a Buy rating for Kura Oncology, which has an average price target of $29.71 based on a Strong Buy consensus.
Kura Oncology 8-K Filing Analysis
Kura Oncology has released its latest 8-K filing, detailing financial results from late 2025 including $2.1 million in KOMZIFTI net product revenue and $195 million in collaboration milestone payments. The company highlighted the full FDA approval of KOMZIFTI, its designation as a Category 2A recommended treatment, and initiation of a Phase 3 trial for newly diagnosed AML patients. Kura Oncology anticipates continued revenue growth for KOMZIFTI and expects its strong cash position to support its ziftomenib AML program through key clinical milestones.
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Kura Oncology reported $2.1 million in preliminary net product revenue for KOMZIFTI™ (ziftomenib) during its initial five weeks post-launch, following its FDA approval in November 2025 for relapsed or refractory NPM1-mutated AML. The company also detailed anticipated 2026 milestones, including commercial acceleration of KOMZIFTI, advancement of ziftomenib development into new combinations and indications, progress with darlifarnib, and preclinical pipeline advancements. Kura Oncology ended 2025 with $667.3 million in cash, which is expected to support its AML program through topline results in the front-line Phase 3 trial.
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Kura Oncology reports preliminary KOMZIFTI revenue of $2.1 million from its recent launch and outlines key milestones for 2026. The company secured FDA approval for KOMZIFTI, an oral menin inhibitor, for adult patients with R/R NPM1-mutated AML and aims to accelerate its U.S. uptake while advancing ziftomenib and darlifarnib development. Kura boasts a solid cash position of $667.3 million to support its ongoing programs.
Kura Oncology Posts $2.1M Initial KOMZIFTI Sales, Secures $195M Milestone
Kura Oncology reported $2.1 million in initial KOMZIFTI sales during its first five weeks of commercial availability and secured $195 million in milestone payments from its collaboration with Kyowa Kirin. The company ended 2025 with $667.3 million in cash and investments and anticipates additional collaboration revenue in 2026. KOMZIFTI, approved for relapsed or refractory AML with an NPM1 mutation, is expected to drive significant revenue growth as Kura expands its U.S. uptake and clinical programs.
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Kura Oncology released preliminary Q4 2025 financial highlights, including $2.1 million in KOMZIFTI net product revenue and $667.3 million in cash and investments. The company highlighted the recent FDA approval of KOMZIFTI for R/R NPM1-mutated AML and outlined key commercial and development milestones for 2026, including accelerating U.S. uptake and advancing various clinical trials for ziftomenib, darlifarnib, and next-generation menin inhibitors.
Kura Oncology Announces Launch of KOMZIFTI™ (ziftomenib) and Preliminary $2.1 Million Revenue Following FDA Approval for R/R NPM1-mutated AML
Kura Oncology has announced the launch of KOMZIFTI™ (ziftomenib), the first oral menin inhibitor approved by the FDA for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Since its commercial release on November 21, 2025, the drug has generated $2.1 million in net product revenue. The company is poised for significant advancements in 2026 with a robust pipeline and strong financial standing, aiming for accelerated U.S. uptake and quarter-over-quarter revenue growth.
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Kura Oncology reported preliminary KOMZIFTI net product revenue of $2.1 million from its first commercial sales period and announced $195 million in milestone payments. The company is poised for significant progress in 2026, aiming to accelerate KOMZIFTI uptake, advance its ziftomenib development pipeline, and explore new indications. Kura Oncology also provided financial guidance and detailed the safety information for KOMZIFTI, emphasizing potential risks like differentiation syndrome and QTc interval prolongation.
Kura Oncology wins FDA approval for leukemia drug
Kura Oncology has secured FDA approval for its new leukemia drug. This approval marks a significant milestone for the company and provides a new treatment option for patients. Further details about the drug's efficacy and market launch are anticipated.
